WO2020144535A1 - Méthodes et compositions de traitement de myélome multiple - Google Patents

Méthodes et compositions de traitement de myélome multiple Download PDF

Info

Publication number
WO2020144535A1
WO2020144535A1 PCT/IB2020/000020 IB2020000020W WO2020144535A1 WO 2020144535 A1 WO2020144535 A1 WO 2020144535A1 IB 2020000020 W IB2020000020 W IB 2020000020W WO 2020144535 A1 WO2020144535 A1 WO 2020144535A1
Authority
WO
WIPO (PCT)
Prior art keywords
april
antibody
protein
level
patient
Prior art date
Application number
PCT/IB2020/000020
Other languages
English (en)
Inventor
John DULOS
Hans Van Eenennaam
Lars GUELEN
Andrea Van Elsas
Original Assignee
Aduro Biotech Holdings, Europe B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aduro Biotech Holdings, Europe B.V. filed Critical Aduro Biotech Holdings, Europe B.V.
Publication of WO2020144535A1 publication Critical patent/WO2020144535A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present invention relates to the measurement of blood, serum, or plasma APRIL levels and the use of such levels in guiding treatment of multiple myeloma with anti-APRIL agents.
  • MM Multiple myeloma
  • plasma cells terminalally differentiated B -cells
  • MMCs malignant myeloma cells
  • MMCs produce monoclonal proteins of varying types, most commonly immunoglobulins and free immunoglobulin light chains, resulting in abnormally high levels of these proteins in the blood.
  • MMCs malignant myeloma cells
  • MM replacement of normal bone marrow by infiltrating tumor cells and inhibition of normal red blood cell production leads to anemia, and renal injury from the high levels of these proteins or light chains is common. Neurological symptoms are also common due to hyperviscosity of the blood.
  • MM is the second most prevalent hematologic malignancy, with an estimated global incidence of 102,000 new cases and a global mortality of 72,000 cases yearly and a 5-year survival rate of approximately 35%. Despite recent progress in the treatment of MM, it remains an incurable condition.
  • B cell activating factor (BAFF) and A PRoliferation-Inducing Ligand
  • APRIL both members of the tumour necrosis factor (TNF) family, represent two of the main survival factors for immature, naive and activated B cells.
  • BAFF binds to B cell maturation antigen (BCMA), transmembrane activator and calcium modulator and cyclophilin ligand receptor (TACI) and BAFF receptor.
  • BCMA B cell maturation antigen
  • TACI transmembrane activator and calcium modulator and cyclophilin ligand receptor
  • APRIL binds to BCMA, TACI and heparin-sulfate proteoglycans. When bound to heparan sulphate proteoglycans, APRIL reportedly ligates TACI and activate NF-KB signaling.
  • MMCs can bind APRIL, which is believed to increase MMC survival and proliferation.
  • APRIL is produced by osteoclasts in the bone marrow.
  • primary myeloma cells, thyroid tissues, lymphoid tissues (e.g., monocytes and macrophages), and various cancers also reportedly express APRIL.
  • Serum APRIL levels are reportedly somewhat elevated in newly diagnosed MM patients as compared to healthy volunteers, with levels increasing with ISS stage. These serum levels are reduced by treatment with chemotherapy in patients exhibiting at least a partial remission of their disease, but are not reduced in stable disease patients. See, e.g., Bolkun et al., Ann. Hematol. 93: 635-44, 2014.
  • Anti-human APRIL antibodies that block APRIL binding to BCMA and TACI have been described, and their potential for further development as therapeutics to target APRIL-dependent survival of MMCs have been described. See, e.g., Guadagnoli et al., Blood 117: 6856-65, 2011; W02010100056.
  • the present invention relates to methods and compositions for the treatment of diseases related to APRIL signaling, and in particular to treatment of multiple myeloma.
  • the invention provides methods of treating a multiple myeloma patient with an anti-APRIL antibody, comprising: measuring a first level of APRIL protein in a first blood, serum, or plasma sample obtained from the patient using an APRIL specific binding assay; following obtaining the first level of APRIL protein, administering a first therapeutic amount of an anti-APRIL antibody to the patient; following the administering, determining one or more monitoring levels of APRIL protein in the patient in one or more blood, serum, or plasma samples obtained from the patient using the APRIL specific binding assay; wherein if one of the monitoring levels indicates an initial reduction in the level of APRIL protein relative to the first level of APRIL protein, and a subsequent one of the monitoring levels indicates an increase in levels of APRIL protein relative to the initial reduction, administering a second therapeutic amount of the anti-APRIL antibody to the patient.
  • one of the monitoring levels fails to indicate an initial reduction in the level of APRIL protein relative to the first level of APRIL protein, administration of the anti-APRIL antibody to the patient is discontinued.
  • the anti-APRIL antibody being administered is selected for the ability to block the binding of APRIL with human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and with human B cell maturation antigen (BCMA) with an IC 50 of about 2 nM or lower.
  • TACI human transmembrane activator and calcium modulator and cyclophilin ligand interactor
  • BCMA human B cell maturation antigen
  • Suitable anti-APRIL antibodies include those described in W02016110587A1, which is hereby incorporated by reference in its entirety.
  • Preferred antibodies are APRIL.01A, APRIL.01A_VH14_1G/VL15 or APRIL.03A.
  • the method provides a correlation of APRIL protein levels in a blood, serum, or plasma sample (measured using the APRIL specific binding assay) and a level of APRIL protein in bone marrow supernatants at the same time point that has a correlation coefficient of at least 0.7, more preferably 0.8, and most preferably 0.85 or more, indicating that the level of APRIL protein being measured in blood, serum, or plasma provides a reasonable measure of corresponding bone marrow levels. This permits monitoring of treatment efficacy without a need for continued bone marrow sampling.
  • Figure 1 depicts the longitudinal monitoring of free APRIL levels in serum samples from multiple myeloma patients that were treated with 150 mg BION-1301 in the ADU-CL-16 clinical trial (NCT03340883). Serum samples were collected before dose 1, at 30 minutes, 1 hour, 2 hours, 4-8 hours, 2 days, 3 days and 8 days post-dose 1, and prior to and 30 minutes after the cycle 1-day 15 and cycle 1-day 29 doses. Vertical dotted lines indicate dosing times. Values below the limit of quantification in the assay are plotted as 0 ng/mL.
  • APRIL protein in vitro techniques for detection of APRIL protein illustratively include one or more of enzyme linked immunosorbent assays (ELISAs), radioimmunoassay, western blot, immunoprecipitation, immunofluorescence, mass spectrometry, liquid
  • An exemplary process for detecting the presence or absence of APRIL protein in a biological sample involves obtaining a biological sample from a subject, such as a human, contacting the biological sample with a compound or an agent capable of detecting of the marker being analyzed, illustratively including an antibody or aptamer, and analyzing binding of the compound or agent to the sample after washing. Those samples having specifically bound compound or agent express the marker being analyzed. Any suitable molecule that can specifically bind to a biomarker is operative in the invention to provide a specific assay for APRIL protein.
  • an agent for detecting APRIL protein is an antibody capable of binding to APRIL protein.
  • immunoassays involve contacting a sample containing or suspected of containing a biomarker of interest with at least one antibody that specifically binds to the biomarker. A signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices are well known to the skilled artisan for the detection and analysis of biomarkers. See, e.g., U.S. Patents 6,143,576; 6,113,855; 6,019,944; 5,985,579;
  • Antibodies or other binding species may be immobilized onto a variety of solid supports for use in assays.
  • Solid phases that may be used to immobilize specific binding members include those developed and/or used as solid phases in solid phase binding assays.
  • suitable solid phases include membrane filters, cellulose- based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates.
  • An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support.
  • Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the latter case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.
  • Biological assays require methods for detection, and one of the most common methods for quantitation of results is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied.
  • Detectable labels may include molecules that are themselves detectable (e.g ., fluorescent moieties, electrochemical labels, metal chelates, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or by a specific binding molecule which itself may be detectable (e.g., biotin, digoxigenin, maltose, oligohistidine, 2,4- dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).
  • a detectable reaction product e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.
  • Cross-linking reagents contain at least two reactive groups, and are divided generally into homobifunctional cross-linkers (containing identical reactive groups) and heterobifunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non- specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups.
  • Antibodies for use in the claimed methods may be obtained from a variety of species.
  • the antibodies of the present invention may comprise
  • immunoglobulin sequences which are rabbit, mouse, rat, guinea pig, chicken, goat, sheep, donkey, human, llama or camelid sequences, or combinations of such sequences (so- called chimeric antibodies). Such antibodies may also be monoclonal or polyclonal.
  • Antibodies for use in the present invention may be identified by their performance in immunoassays, and then further characterized by epitope mapping in order to understand the epitopes which are relevant to that performance.
  • Preferred are rabbit antibodies or humanized versions derived from rabbit antibodies.
  • Such antibodies may be conjugated to a signal development element or immobilized on a solid support.
  • such antibodies may be used in a number of competitive and sandwich assay formats.
  • a first antibody detectably labeled
  • a second antibody immobilized at a predetermined zone of a test device
  • sandwich complexes with APRIL protein in the sample at a predetermined zone of a test device.
  • the first and second antibodies can be the same (particularly when polyclonal antibodies are used) or different.
  • an anti-APRIL antibody may be used in sandwich pairs, or may be used individually with another binding entity which is not a monoclonal antibody such as a polyclonal antibody or an aptamer.
  • Methods for making aptamers with a particular binding specificity are known as detailed in U.S. Pat. Nos. 5,475,096; 5,670,637; 5,696,249; 5,270,163;
  • Antibodies or other binding species can be used as reagents in test kits for detecting APRIL protein in biological samples.
  • a test kit may, for example, comprise a disposable test device configured to generate a detectable signal related to the present or amount of human APRIL protein in a biological sample.
  • a test kit may be formulated for performing an assay in a clinical analyzer which does not utilize a disposable test device.
  • the test kit is an in vitro diagnostic.
  • in vitro diagnostic refers to a medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment, or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information concerning a physiological or pathological state, or concerning a congenital abnormality, or to determine the safety and compatibility with potential recipients, or to monitor therapeutic measures.
  • the binding assay is performed in a lateral flow format.
  • Lateral flow tests are a form of immunoassay in which the test sample flows in a chromatographic fashion along a bibulous or non-bibulous porous solid substrate. Lateral flow tests can operate as either competitive or sandwich format assays.
  • Preferred lateral flow devices are disposable, single use test devices. A sample is applied to the test device at an application zone and transits the substrate, where it encounters lines or zones which have been pretreated with an antibody or antigen.
  • the term“test zone” as used herein refers to a discrete location on a lateral flow test strip which is interrogated in order to generate a signal related to the presence or amount of an analyte of interest.
  • the detectable signal may be read visually or obtained by inserting the disposable test device into an analytical instrument such as a reflectometer, a fluorometer, or a transmission photometer.
  • an analytical instrument such as a reflectometer, a fluorometer, or a transmission photometer.
  • Sample may be applied without pretreatment to the application zone, or may be premixed with one or more assay reagents prior to application. In the latter case, the antibody may be provided in a separate container from the disposable test device.
  • An antibody of the present invention may be diffusively immobilized to a surface within a disposable test device, such that the antibody dissolves into a sample when the sample contacts the surface.
  • this diffusively bound antibody may bind to its cognate antigen in the sample, and then be immobilized at a detection zone when the antigen is bound by a second antibody non-diffusively bound at the detection zone.
  • its cognate antigen in the sample may compete for binding to the diffusively bound antibody with a labeled antigen provided as an assay reagent.
  • a kit of the invention can further comprise a calibration to relate the detectable signal to a concentration of APRIL protein.
  • a calibration curve may be provided on an electronic memory device which is read by the analytical instrument which receives the disposable test device, such as a ROM chip, a flash drive, an RFID tag, etc.
  • the calibration curve may be provided on an encoded label which is read optically, such as a 2-D bar code, or transmitted via a network connection. The analytical instrument can then use this calibration curve to relate a detectable signal from an assay into a APRIL protein concentration
  • the terms“correlating” and“relating” as used herein in reference to the measurement of biomarkers in an assay refers to determining the presence, or more preferably the amount, of the biomarker in a sample based on the signal obtained from the assay. Often, this takes the form of comparing a signal generated from a detectable label on one species participating in the assay to a predetermined standard curve which can be used to convert the signal to a concentration or threshold amount of the biomarker.
  • the terms“correlating” and“relating” as used herein in reference to the use of biomarkers for selecting a treatment regimen refers to comparing a measured value to a threshold selected to distinguish an individual that would benefit from a treatment regimen from an individual that would not benefit.
  • one method for selecting may be to look at serial samples from the same patient, where a prior“baseline” result is used to monitor for temporal changes in a biomarker level.
  • a population study may be used to select a decision threshold.
  • Receiver Operating Characteristic arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold able to best distinguish a“diseased” subpopulation from a“nondiseased” subpopulation.
  • a false positive in this case occurs when the person tests positive, but actually does not have the disease.
  • a false negative occurs when the person tests negative, suggesting they are healthy, when they actually do have the disease.
  • TPR true positive rate
  • FPR false positive rate
  • the ROC graph is sometimes called the sensitivity vs (1 - specificity) plot.
  • a perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5.
  • a threshold is selected to provide an acceptable level of specificity and sensitivity.
  • “diseased” is meant to refer to a population having one characteristic (e.g., benefit from treatment) and“nondiseased” is meant to refer to a population lacking the characteristic.
  • a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.
  • Measures of test accuracy may be obtained as described in Fischer et ak, Intensive Care Med. 29: 1043-51, 2003, and used to determine the effectiveness of a given biomarker. These measures include sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and ROC curve areas.
  • the area under the curve (“AUC”) of a ROC plot is equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one.
  • the area under the ROC curve may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.
  • a suitable antibody or antigen-binding fragment thereof is admixed with a pharmaceutically acceptable carrier or excipient. See, e.g., Remington's Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary , Mack Publishing Company, Easton, PA (1984).
  • Formulations of therapeutic agents may be prepared by mixing with acceptable carriers, excipients, or stabilizers in the form of, e.g., lyophilized powders, slurries, aqueous solutions or suspensions (see, e.g., Hardman, et al. (2001) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, NY; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott,
  • Toxicity and therapeutic efficacy of an anti-APRIL antibody, administered alone or in combination with another therapeutic agent can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index (LD50/ ED50).
  • the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration.
  • a further therapeutic agent is administered to a subject in association with an anti-APRIL antibody or antigen-binding fragment thereof in accordance with the Physicians' Desk Reference 2003 (Thomson Healthcare; 57th edition (November 1, 2002)).
  • the mode of administration can vary. Routes of administration include oral, rectal, transmucosal, intestinal, parenteral; intramuscular, subcutaneous, intradermal, intramedullary, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, intraocular, inhalation, insufflation, topical, cutaneous, transdermal, or intra-arterial.
  • the anti-APRIL antibodies or antigen-binding fragments thereof can be administered by an invasive route such as by injection.
  • an anti-APRIL antibody or antigen-binding fragment thereof, or pharmaceutical composition thereof is administered intravenously, subcutaneously, intramuscularly, intraarterially, intratumorally, or by inhalation, aerosol delivery.
  • Administration by non-invasive routes e.g ., orally; for example, in a pill, capsule or tablet) is also within the scope of the present invention.
  • the present invention provides a vessel (e.g., a plastic or glass vial, e.g., with a cap or a chromatography column, hollow bore needle or a syringe cylinder) comprising any of the antibodies or antigen-binding fragments of the invention or a pharmaceutical composition thereof.
  • a vessel e.g., a plastic or glass vial, e.g., with a cap or a chromatography column, hollow bore needle or a syringe cylinder
  • an injection device comprising any of the antibodies or antigen-binding fragments of the invention or a pharmaceutical composition thereof.
  • An injection device is a device that introduces a substance into the body of a patient via a parenteral route, e.g., intramuscular, subcutaneous or intravenous.
  • an injection device may be a syringe (e.g., pre-filled with the
  • an injection device that comprises an antibody or antigen-binding fragment thereof of the present invention or a pharmaceutical composition thereof is an intravenous (IV) injection device.
  • IV intravenous
  • a device includes the antibody or fragment or a pharmaceutical composition thereof in a cannula or
  • trocar/needle which may be attached to a tube which may be attached to a bag or reservoir for holding fluid (e.g., saline; or lactated ringer solution comprising NaCl, sodium lactate, KCl, CaC 2 and optionally including glucose) introduced into the body of the patient through the cannula or trocar/needle.
  • fluid e.g., saline; or lactated ringer solution comprising NaCl, sodium lactate, KCl, CaC 2 and optionally including glucose
  • the antibody or fragment or a pharmaceutical composition thereof may, in an embodiment of the invention, be introduced into the device once the trocar and cannula are inserted into the vein of a subject and the trocar is removed from the inserted cannula.
  • the IV device may, for example, be inserted into a peripheral vein (e.g., in the hand or arm); the superior vena cava or inferior vena cava, or within the right atrium of the heart ( e.g ., a central IV); or into a subclavian, internal jugular, or a femoral vein and, for example, advanced toward the heart until it reaches the superior vena cava or right atrium (e.g., a central venous line).
  • an injection device is an autoinjector; a jet injector or an external infusion pump.
  • a jet injector uses a high-pressure narrow jet of liquid which penetrate the epidermis to introduce the antibody or fragment or a pharmaceutical composition thereof to a patient’s body.
  • External infusion pumps are medical devices that deliver the antibody or fragment or a pharmaceutical composition thereof into a patient’s body in controlled amounts. External infusion pumps may be powered electrically or
  • a syringe pump holds fluid in the reservoir of a syringe
  • a moveable piston controls fluid delivery
  • an elastomeric pump holds fluid in a stretchable balloon reservoir
  • pressure from the elastic walls of the balloon drives fluid delivery.
  • a set of rollers pinches down on a length of flexible tubing, pushing fluid forward.
  • fluids can be delivered from multiple reservoirs at multiple rates.
  • compositions may also be administered with a needleless hypodermic injection device; such as the devices disclosed in U.S. Patent Nos. 6,620,135; 6,096,002; 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824 or
  • Such needleless devices comprising the pharmaceutical composition are also part of the present invention.
  • the pharmaceutical compositions may also be administered by infusion.
  • implants and modules for administering the pharmaceutical compositions include those disclosed in: U.S. Patent No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Patent No. 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; U.S. Patent No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Patent. No. 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments. Many other such implants, delivery systems, and modules are well known to those skilled in the art and those comprising the pharmaceutical compositions of the present invention are within the scope of the present invention.
  • the liposomes will be targeted to and taken up selectively by the afflicted tissue. Such methods and liposomes are part of the present invention.
  • the administration regimen depends on several factors, including the serum or tissue turnover rate of the therapeutic antibody or antigen-binding fragment, the level of symptoms, the immunogenicity of the therapeutic antibody, and the accessibility of the target cells in the biological matrix.
  • the administration regimen delivers sufficient therapeutic antibody or fragment to effect improvement in the target disease state, while simultaneously minimizing undesired side effects.
  • the amount of biologic delivered depends in part on the particular therapeutic antibody and the severity of the condition being treated. Guidance in selecting appropriate doses of therapeutic antibodies or fragments is available (see, e.g., Wawrzynczak (1996) Antibody Therapy , Bios Scientific Pub.
  • Determination of the appropriate dose is made by the clinician, e.g., using parameters or factors known or suspected in the art to affect treatment. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved relative to any negative side effects.
  • Important diagnostic measures include those of symptoms of, e.g., the inflammation or level of inflammatory cytokines produced. In general, it is desirable that a biologic that will be used is derived from the same species as the animal targeted for treatment, thereby minimizing any immune response to the reagent. In the case of human subjects, for example, humanized and fully human antibodies may be desirable.
  • Antibodies or antigen-binding fragments thereof may be provided by continuous infusion, or by doses administered, e.g., daily, 1-7 times per week, weekly, bi weekly, monthly, bimonthly, quarterly, semiannually, annually etc.
  • Doses may be provided, e.g., intravenously, subcutaneously, topically, orally, nasally, rectally, intramuscular, intracerebrally, intraspinally, or by inhalation.
  • a total weekly dose is generally at least 0.05 mg/kg body weight, more generally at least 0.2 mg/kg, 0.5 mg/kg, 1 mg/kg, 10 mg/kg, 100 mg/kg, 0.25 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 5.0 mg/mL, 10 mg/kg, 25 mg/kg, 50 mg/kg or more (see, e.g., Yang, et al. (2003) New Engl. J. Med. 349:427-434; Herold, et al. (2002) New Engl. J. Med. 346:1692-1698; Liu, et al. (1999) J. Neurol. Neurosurg. Psych. 67: 451-456; Portielji, et al. (20003) Cancer Immunol. Immunother. 52: 151-144). Doses may also be provided to achieve a pre-determined target
  • concentration of anti-APRIL antibody in the subject’s serum such as 0.1, 0.3, 1, 3, 10,
  • an anti-APRIL antibody is administered, e.g., subcutaneously or intravenously, on a weekly, biweekly, "every 4 weeks,” monthly, bimonthly, or quarterly basis at 10, 20, 50, 80, 100, 150, 200, 500 or 1000 mg/subject.
  • an effective amount refers to an amount of an anti- APRIL or antigen-binding fragment thereof that, whether administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective to cause a measurable improvement in one or more symptoms of disease, for example cancer or the progression of cancer.
  • An effective dose further refers to that amount of the antibody or fragment sufficient to result in at least partial amelioration of symptoms, e.g., tumor shrinkage or elimination, lack of tumor growth, increased survival time.
  • an effective dose refers to that ingredient alone.
  • an effective dose refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
  • An effective amount of a therapeutic will result in an improvement of a diagnostic measure or parameter by at least 10%; usually by at least 20%; preferably at least about 30%; more preferably at least 40%, and most preferably by at least 50%.
  • An effective amount can also result in an improvement in a subjective measure in cases where subjective measures are used to assess disease severity.
  • APRIL.01A_VH14_1G/VL15 (referred to herein as“BION-1301”; described in
  • W02016110587A1 was supplied as a solution intended for intravenous (IV) administration to multiple myeloma patients (see
  • BION-1301 was administered at the assigned dose level (50, 150 or 450 mg) by IV infusion over approximately 2 hours using central lines or other venous access devices. Patients were dosed once every two weeks (Q2W) in a 4 weeks cycle.
  • Example 2 Blood and bone marrow sample collection and preparation
  • blood and bone marrow samples were obtained from multiple myeloma patients. Blood samples were collected before treatment with 50 mg or 150 mg BION-1301 and at 30 minutes, 1 hour, 2 hours, 4-8 hours, 2 days, 3 days and 8 days post-dosing. In addition, blood samples were obtained prior to and 30 minutes after the cycle 1-day 15, cycle 1-day 29 and cycle 2 day- 15 doses. Bone marrow samples were collected before treatment with 50mg or 150mg BION-1301 and prior to the cycle 2-day 15 dose.
  • Blood was drawn by venipuncture and collected in vacuum serum separation tubes. After gently inverting the tubes for 5 times, blood was allowed to clot for 30 minutes. The tubes were centrifuged at 1100-1300xg for 10-15 minutes. Serum was collected, aliquoted into cryovials and stored at -70°C until analysis. Bone marrow aspirates were preferably obtained from the iliac crest. The aspirates were collected in sodium heparin tubes and mixed by gently inverting 8-10 times. Tubes were centrifuged at 400xg for 10-15 minutes. Aspirate supernatants were collected and aliquoted into cryovials. Samples were stored at -70°C until analysis.
  • 96- well plates were coated overnight with a recombinant capture antigen (Recombinant Human BCMA, R&D Systems). Coated plates were blotted dry by emptying and tapping on a paper towel. Plates were then blocked for 1-2 hours with 1% BSA in DPBS to prevent non-specific binding of proteins. Standards were prepared by spiking freshly reconstituted recombinant human APRIL (rhAPRIL, R&D Systems) into assay diluent (0.5%BSA and 0.05%Tween 20 in PBS).
  • Matrix QCs, serum samples and bone marrow supernatants were diluted 5-fold in assay diluent. After the blocking incubation, plates were washed three times with wash buffer PBS-T (0.05% Tween 20 in PBS) using an automated plate washer. Then, the standards, diluted QCs, and diluted samples were added, and the plates were incubated for one hour at room temperature. The plates were washed again to remove unbound material, and a 0.5 mg/mL solution of Mouse Anti- hAPRIL ⁇ Monoclonal Antibody hAPRIL.133 (Aduro Biotech Europe) was added.
  • the absorbance was read on a Spectramax Plus 384 spectrophotometer (Molecular Devices) at 450 nm, using 620 nm as reference wavelength. WatsonTM LIMS Version 7.4.1 was used for data analysis. The color intensity was proportional to the amount of free APRIL ⁇ present in the sample.
  • Example 4 Determination of the levels of BION-1301 in human serum and bone marrow supernatants
  • BION-1301 was quantified in human serum and bone marrow supernatant using a sandwich Electrochemiluminescence (ECL) immunoassay.
  • ECL Electrochemiluminescence
  • Example 5 Results [0058] Table 1 shows the levels of free APRIL and BION-1301 that were measured in serum and bone marrow samples, collected from multiple myeloma patients before dosing with 50 mg or 150 mg BION-1301 and prior to the cycle 2-day 15 dose. The measurements that were performed on 8 paired serum and bone marrow samples demonstrate that both compartments contain highly comparable levels of free APRIL. In addition, determination of BION-1301 levels in 2 paired serum and bone marrow samples shows that the antibody concentration is highly comparable in the two compartments.
  • Figure 1 depicts the longitudinal monitoring of free APRIL levels in serum from multiple myeloma patients treated with BION-1301. Dosing with BION-1301 resulted in an instant reduction of serum free APRIL levels. Over time these levels showed partial recovery and a sharp decline upon subsequent dosing with BION-1301. In view of the comparable levels of free APRIL in serum and bone marrow, this longitudinal monitoring of serum free APRIL levels is indicative of the dynamics of free APRIL levels in bone marrow upon treatment with BION-1301.
  • the optimal dosing level and/or schedule of an APRIL-neutralizing antibody such as BION-1301, or other treatments aimed at affecting bone marrow free APRIL levels can be based on the free APRIL levels measured in corresponding serum samples.
  • the term“about” refers to a range of values which are 10% more or less than the specified value. In another embodiment, the term“about” refers to a range of values which are 5% more or less than the specified value. In another embodiment, the term“about” refers to a range of values which are 1% more or less than the specified value.
  • ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.
  • the terms“between X and Y” and “range from X to Y are inclusive of X and Y and the integers there between.
  • any range including any of the two individual values as the two end points is also conceived in this disclosure.
  • the expression“a dose of about 100 mg, 200 mg, or 400 mg” can also mean“a dose ranging from 100 to 200 mg”,“a dose ranging from 200 to 400 mg”, or “a dose ranging from 100 to 400 mg”.

Abstract

La présente invention concerne des méthodes et des compositions de traitement de maladies liées à la signalisation APRIL, et en particulier le traitement de myélome multiple.
PCT/IB2020/000020 2019-01-08 2020-01-07 Méthodes et compositions de traitement de myélome multiple WO2020144535A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962789699P 2019-01-08 2019-01-08
US62/789,699 2019-01-08

Publications (1)

Publication Number Publication Date
WO2020144535A1 true WO2020144535A1 (fr) 2020-07-16

Family

ID=69726620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/000020 WO2020144535A1 (fr) 2019-01-08 2020-01-07 Méthodes et compositions de traitement de myélome multiple

Country Status (1)

Country Link
WO (1) WO2020144535A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150778A1 (fr) * 2022-02-07 2023-08-10 Visterra, Inc. Molécules d'anticorps anti-idiotype et leurs utilisations
US11959924B2 (en) 2013-09-06 2024-04-16 Aduro Biotech Holdings, Europe B.V. Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5480792A (en) 1990-09-14 1996-01-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5525524A (en) 1991-04-10 1996-06-11 Biosite Diagnostics, Inc. Crosstalk inhibitors and their uses
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5595877A (en) 1990-06-11 1997-01-21 Nexstar Pharmaceuticals, Inc. Methods of producing nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5679526A (en) 1989-01-10 1997-10-21 Biosite Diagnostics Incorporated Threshold ligand-receptor assay
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US5851776A (en) 1991-04-12 1998-12-22 Biosite Diagnostics, Inc. Conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6620135B1 (en) 1998-08-19 2003-09-16 Weston Medical Limited Needleless injectors
WO2010100056A2 (fr) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Anticorps contre le ligand a induisant la prolifération (april)
WO2016110587A1 (fr) 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Anticorps de liaison de la protéine april modifiés

Patent Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5679526A (en) 1989-01-10 1997-10-21 Biosite Diagnostics Incorporated Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5595877A (en) 1990-06-11 1997-01-21 Nexstar Pharmaceuticals, Inc. Methods of producing nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5670637A (en) 1990-06-11 1997-09-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5696249A (en) 1990-06-11 1997-12-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands
US5985579A (en) 1990-09-14 1999-11-16 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5480792A (en) 1990-09-14 1996-01-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5525524A (en) 1991-04-10 1996-06-11 Biosite Diagnostics, Inc. Crosstalk inhibitors and their uses
US5851776A (en) 1991-04-12 1998-12-22 Biosite Diagnostics, Inc. Conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5399163A (en) 1992-07-24 1995-03-21 Bioject Inc. Needleless hypodermic injection methods and device
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6620135B1 (en) 1998-08-19 2003-09-16 Weston Medical Limited Needleless injectors
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
WO2010100056A2 (fr) 2009-03-02 2010-09-10 Stichting Top Institute Pharma Anticorps contre le ligand a induisant la prolifération (april)
WO2016110587A1 (fr) 2015-01-09 2016-07-14 Aduro Biotech Holdings, Europe B.V. Anticorps de liaison de la protéine april modifiés

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases", 1993, MARCEL DEKKER
"Monoclonal Antibodies, Cytokines and Arthritis", 1991, MARCEL DEKKER
"Pharmaceutical Dosage Forms: Disperse Systems", 1990, MARCEL DEKKER
"Physicians' Desk Reference 2003", 1 November 2002, THOMSON HEALTHCARE
"Remington's Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary", 1984, MACK PUBLISHING COMPANY
"The Immunoassay Handbook", 1994, STOCKTON PRESS
BENIAMINOVITZ ET AL., NEW ENGL. J. MED., vol. 343, 2000, pages 1594 - 1602
BOLKUN ET AL., ANN. HEMATOL., vol. 93, 2014, pages 635 - 44
DULOS JOHN ET AL: "Bion-1301, a First-in-Class APRIL Neutralizing Antibody for the Treatment of Multiple Myeloma: Preclinical Safety, and Analysis of Pharmacokinetics - Pharmacodynamics Relationship", 7 December 2017, BLOOD, VOL. 130, NR. SUPPL. 1, PAGE(S) 1827, 59TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH); ATLANTA, GA, USA; DECEMBER 09 -12, 2017, ISSN: 0006-4971(print), XP009520077 *
FISCHER ET AL., INTENSIVE CARE MED., vol. 29, 2003, pages 1043 - 51
GHOSH ET AL., NEW ENGL. J. MED., vol. 349, 2003, pages 427 - 434
GUADAGNOLI ET AL., BLOOD, vol. 117, 2011, pages 6856 - 65
HEROLD ET AL., NEW ENGL. J. MED., vol. 346, 2002, pages 1692 - 1698
JOHN DULOS: "Abstract 3780: Preclinical pharmacokinetics, pharmacodynamics and safety of BION-1301, a first-in-class antibody targeting APRIL for the treatment of multiple myeloma", CANCER RESEARCH, vol. 78, no. 13, 1 July 2018 (2018-07-01), XP055688411, DOI: 10.1158/1538-7445.AM2018-3780 *
LIU ET AL., J. NEUROL. NEUROSURG. PSYCH., vol. 67, 1999, pages 451 - 456
MILGROM ET AL., NEW ENGL. J. MED., vol. 341, 1999, pages 1966 - 1973
PORTIELJI ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, pages 151 - 144
SLAMON ET AL., NEW ENGL. J. MED., vol. 344, 2001, pages 783 - 792
WAWRZYNCZAK: "Antibody Therapy", 1996, BIOS SCIENTIFIC PUB. LTD

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11959924B2 (en) 2013-09-06 2024-04-16 Aduro Biotech Holdings, Europe B.V. Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample
WO2023150778A1 (fr) * 2022-02-07 2023-08-10 Visterra, Inc. Molécules d'anticorps anti-idiotype et leurs utilisations

Similar Documents

Publication Publication Date Title
RU2137130C1 (ru) Способ раннего определения, определения тяжести заболевания и оценка процесса лечения сепсиса, а также средства для осуществления указанного способа
CN110709103B (zh) 用于生物学样品中具有改善的性能的timp2的测定法
WO2020144535A1 (fr) Méthodes et compositions de traitement de myélome multiple
EP0925503A1 (fr) Substances et methodes relatives au diagnostic et au traitement du diabete et de l'obesite
BR112021003093A2 (pt) tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
CN112105387A (zh) 特应性皮炎的治疗
JP6564435B2 (ja) アルファ４ベータ７ヘテロ二量体特異抗体の投与
US20150093331A1 (en) Biomarkers for breast cancer
KR102626197B1 (ko) 항 약물 항체의 수준을 정확하게 정량화하는 방법
JP2021509120A (ja) Ｃｃｌ１４に関する抗体およびアッセイ
EP3619536A1 (fr) Méthodes de traitement sélectif de l'asthme au moyen d'antagonistes de l'il-17
CN114341178B (zh) Ccl14的抗体和检测
WO2020237491A1 (fr) Composition et méthodes pour le traitement d'une dysplasie ectodermique 2, type clouston
US20220275097A1 (en) Antibody to leptin receptor
US20150157647A1 (en) Methods and compositions related to acute respiratory distress syndrome
WO2024013234A1 (fr) Méthodes de diagnostic, de pronostic, de stratification et de traitement de la myocardite
CN102830223A (zh) 一种筛选治疗哺乳动物肿瘤疾病药物的方法
US20150338397A1 (en) Use of Bufodienolides in Diagnosing and Treating Essential Hypertension
EP2613152A9 (fr) Sensibilisateur pour agent diagnostique érythrocytaire utilisé dans le diagnostic de tumeurs malignes et son procédé de production, agent diagnostique érythrocytaire pour le diagnostic de tumeurs malignes et son procédé de production et méthode de diagnostic de tumeurs malignes utilisant ledit agent diagnostique érythrocytaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20708163

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20708163

Country of ref document: EP

Kind code of ref document: A1